enGene Holdings Inc. (ENGN), a clinical-stage genetic medicines company, has an upcoming clinical trial catalyst to keep an eye on in the coming months.
The company's lead product candidate is EG-70, a novel non-viral gene therapy being developed for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com